OPK
Opko Health Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Market Cap: 654 Million
Primary Exchange: NASDAQ
Website: http://www.opko.com/
Shares Outstanding: 697 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.270698211631279
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1792 trading days
From: 2015-06-03 To: 2024-03-07
Lowest Point:
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
Portfolio Composition: Short Commodity, Precious Metals; Long Rare Earths, Biotech
via: SeekingAlpha at 2019-06-10 23:35:41:000
According the CME FedWatch tool, Fed Funds futures markets are currently pricing in a 98.5% chance of the Federal Reserve lowering rates at least once this year. Breaking it down further, there is a 31.9% probability of 2 rate cuts and a 35.4% chance of three 25 basis point rate decreases, as … read more...
Portfolio Composition: Short Commodity, Precious Metals; Long Rare Earths, Biotech
via: SeekingAlpha at 2019-06-10 23:35:41:000
According the CME FedWatch tool, Fed Funds futures markets are currently pricing in a 98.5% chance of the Federal Reserve lowering rates at least once this year. Breaking it down further, there is a 31.9% probability of 2 rate cuts and a 35.4% chance of three 25 basis point rate decreases, as … read more...
Portfolio Composition: Short Commodity, Precious Metals; Long Rare Earths, Biotech
via: SeekingAlpha at 2019-06-10 23:35:41:000
According the CME FedWatch tool, Fed Funds futures markets are currently pricing in a 98.5% chance of the Federal Reserve lowering rates at least once this year. Breaking it down further, there is a 31.9% probability of 2 rate cuts and a 35.4% chance of three 25 basis point rate decreases, as … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|